|Slideshows|December 13, 2016

A Case of Gambling Disorder

Author(s)Iman Parhami, MD, MPH, Timothy W. Fong, MD

A patient is brought to the emergency department by her daughter for bizarre behavior and symptoms of mania after gambling from the casino for 48 continuous hours.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Innovative Sciences: Eric Nestler, MD, PhD Reflects on Research and Leadership in Medicine

ByEric J. Nestler, MD, PhD

January 21st 2026

Precision Medicine for Opioid Use Disorder: Insights From New Review

ByPoorvanshi Alag, MD,Jessica Walters

January 19th 2026

Do ADHD Stimulant Medications Have an Effect on Substance Use?

ByJessica Walters

January 18th 2026

A Network-Based Approach to Depression, Neuropathic Pain, and Substance Use Disorder Using Coadministered TMS and Ketamine

BySteven R. Devore Best, MD

January 15th 2026

Patent Issued for Rezenopy, the Highest Dosage Naloxone Nasal Spray Approved by the FDA

ByLeah Kuntz

January 14th 2026

Latest CME

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

A Case of Gambling Disorder

Newsletter

Related Content

Innovative Sciences: Eric Nestler, MD, PhD Reflects on Research and Leadership in Medicine

Precision Medicine for Opioid Use Disorder: Insights From New Review

Do ADHD Stimulant Medications Have an Effect on Substance Use?

A Network-Based Approach to Depression, Neuropathic Pain, and Substance Use Disorder Using Coadministered TMS and Ketamine

Patent Issued for Rezenopy, the Highest Dosage Naloxone Nasal Spray Approved by the FDA

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Trending on Psychiatric Times

Phase 2 Study Initiated for NBI-1065890 to Treat Tardive Dyskinesia

Phase 2 Trial Initiated: LB-102 for Bipolar Depression

Major Depressive Disorder Research Roundup: January 23, 2026

Preparing to be 80: Important Considerations for Psychiatry and Society

Celebrating 60 Years of Social Psychiatry at the 25th World Congress of Social Psychiatry